- Home
- SGA vs HRTX Comparison
SGA vs HRTX Comparison
Compare SGA & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$8.97
HOLD
Current Price
$0.31
Company Overview
Basic Information| Metric | SGA | HRTX |
|---|---|---|
| Founded | 1986 | 1983 |
| Country | United States | United States |
| Employees | N/A | 128 |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 61.2M |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SGA | HRTX |
|---|---|---|
| Price | $8.97 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 17.6K | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $124,829,000.00 | ★ $154,904,000.00 |
| Revenue This Year | $6.74 | $15.28 |
| Revenue Next Year | N/A | $20.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.65 | ★ 7.36 |
| 52 Week Low | $8.24 | $0.30 |
| 52 Week High | $13.05 | $1.58 |
Technical Indicators
Market Signals| Indicator | SGA | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 40.13 |
| Support Level | $8.36 | $0.30 |
| Resistance Level | $9.42 | $0.34 |
| Average True Range (ATR) | 0.30 | 0.02 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 25.24 | 41.64 |
Price Performance
Historical Comparison SGA
HRTX
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.